The below Access Programs* are regulated frameworks put in place by pharmaceutical manufacturers to allow physicians to request access to specific medicines where their patient is unable to access that medicine through clinical trials or via the usual commercial route.
The decision to treat a patient as part of an access program is based on the clinical judgment of their physician, and is applicable where there is a genuine unmet medical need and no alternative treatments available. The registry has been developed by CheckOrphan, in collaboration with Idis, to create a resource for the rare disease community who wish to access a specific medicine, but find that it is currently unavailable to them.
The listings include information about the therapeutic areas and specific indications where such access programs have been put in place by pharmaceutical manufacturers. Due to regulations governing unlicensed medicines, entries submitted to CheckOrphan for review and publication will not be mentioning product names. Where product names are mentioned on any detail pages, this information is taken from other publicly available sources.
* The term “Access Program” is intended as an umbrella term to bring together the varied terminology used by regulators in different jurisdictions, and by different specialist partners operating in this context.